Tandem Diabetes Care Inc
NASDAQ:TNDM
Tandem Diabetes Care Inc
Accounts Payable
Tandem Diabetes Care Inc
Accounts Payable Peer Comparison
Competitive Accounts Payable Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Accounts Payable
$48.1m
|
CAGR 3-Years
20%
|
CAGR 5-Years
34%
|
CAGR 10-Years
37%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Accounts Payable
$5.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
11%
|
|
Boston Scientific Corp
NYSE:BSX
|
Accounts Payable
$921m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
14%
|
|
Stryker Corp
NYSE:SYK
|
Accounts Payable
$1.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
14%
|
|
Abbott Laboratories
NYSE:ABT
|
Accounts Payable
$4.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accounts Payable
$194.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
8%
|
CAGR 10-Years
13%
|
See Also
What is Tandem Diabetes Care Inc's Accounts Payable?
Accounts Payable
48.1m
USD
Based on the financial report for Mar 31, 2024, Tandem Diabetes Care Inc's Accounts Payable amounts to 48.1m USD.
What is Tandem Diabetes Care Inc's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
37%
Over the last year, the Accounts Payable growth was -13%. The average annual Accounts Payable growth rates for Tandem Diabetes Care Inc have been 20% over the past three years , 34% over the past five years , and 37% over the past ten years .